iBio Inc. Annual report pursuant to Section 13 and 15(d)

Share-Based Compensation (Tables)

12 Months Ended

Jun. 30, 2013

The following table summarizes the components of share-based compensation expense in the Statements of Operations (in thousands):

	For the Years Ended June 30,
	2013		2012
Research and development	$	192	$	191
General and administrative		1,071		2,492
Total share-based compensation	$	1,263	$	2,683

The following table summarizes all stock option activity for the year ended June 30, 2013:

	Stock Options		Weighted- average Exercise Price		Weighted- average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding as of June 30, 2012		5,510,000	$	1.56		8.1	$	494
Granted		1,330,000	$	1.02
Forfeited		(80,000)	$	1.55
Outstanding as of June 30, 2013		6,760,000	$	1.45		7.5	$	161
Vested and expected to vest as of June 30, 2013		6,736,548	$	1.45		7.5	$	161

Exercisable as of June 30, 2013		4,266,604	$	1.54		7.0	$	139

The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions: